Muriel D David

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7847273/publications.pdf

Version: 2024-02-01

27 papers

2,357 citations

331670 21 h-index 27 g-index

27 all docs

27 docs citations

times ranked

27

3960 citing authors

#	Article	IF	CITATIONS
1	AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> Mutations. Cancer Discovery, 2017, 7, 478-493.	9.4	350
2	Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood, 2017, 130, 732-741.	1.4	300
3	Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers. ACS Medicinal Chemistry Letters, 2018, 9, 300-305.	2.8	292
4	Distinct Structural Features of Caprin-1 Mediate Its Interaction with G3BP-1 and Its Induction of Phosphorylation of Eukaryotic Translation Initiation Factor 2α, Entry to Cytoplasmic Stress Granules, and Selective Interaction with a Subset of mRNAs. Molecular and Cellular Biology, 2007, 27, 2324-2342.	2.3	213
5	Epigenetic Enhancement of Antigen Processing and Presentation Promotes Immune Recognition of Tumors. Cancer Research, 2008, 68, 9601-9607.	0.9	166
6	Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. Nature Medicine, 2018, 24, 1167-1177.	30.7	157
7	GILZ, a new target for the transcription factor FoxO3, protects T lymphocytes from interleukin-2 withdrawal–induced apoptosis. Blood, 2004, 104, 215-223.	1.4	139
8	Induction of the IL-13 receptor α2-chain by IL-4 and IL-13 in human keratinocytes: involvement of STAT6, ERK and p38 MAPK pathways. Oncogene, 2001, 20, 6660-6668.	5.9	94
9	Cell cycle regulation of Rho signaling pathways. Cell Cycle, 2012, 11, 3003-3010.	2.6	76
10	Epigenetic Control of the Immune Escape Mechanisms in Malignant Carcinomas. Molecular and Cellular Biology, 2007, 27, 7886-7894.	2.3	69
11	Distinct Mechanisms Determine the Patterns of Differential Activation of H-Ras, N-Ras, K-Ras 4B, and M-Ras by Receptors for Growth Factors or Antigen. Molecular and Cellular Biology, 2004, 24, 6311-6323.	2.3	65
12	Absence of Caprin-1 Results in Defects in Cellular Proliferation. Journal of Immunology, 2005, 175, 4274-4282.	0.8	60
13	The glucocorticoid receptor and STAT6 physically and functionally interact in T-lymphocytes. FEBS Letters, 2000, 487, 229-233.	2.8	55
14	AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo. Blood, 2014, 124, 3734-3734.	1.4	38
15	Functional characterization of IL-13 receptor $\hat{l}\pm2$ gene promoter: a critical role of the transcription factor STAT6 for regulated expression. Oncogene, 2003, 22, 3386-3394.	5.9	37
16	Binding of IL-4 to the IL- $13R\hat{l}\pm1$ /IL- $4R\hat{l}\pm$ receptor complex leads to STAT3 phosphorylation but not to its nuclear translocation. FEBS Letters, 1999, 464, 91-96.	2.8	34
17	Pure Lipopolysaccharide or Synthetic Lipid A Induces Activation of p21Ras in Primary Macrophages through a Pathway Dependent on Src Family Kinases and PI3K. Journal of Immunology, 2005, 175, $8236-8241$.	0.8	30
18	Suppressor of cytokine signaling 1 modulates invasion and metastatic potential of colorectal cancer cells. Molecular Oncology, 2014, 8, 942-955.	4.6	30

#	ARTICLE	IF	CITATIONS
19	Quantitation of isocitrate dehydrogenase (IDH)-induced D and L enantiomers of 2-hydroxyglutaric acid in biological fluids by a fully validated liquid tandem mass spectrometry method, suitable for clinical applications. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1022, 290-297.	2.3	30
20	Identification of Mechanisms Underlying Transporter Associated with Antigen Processing Deficiency in Metastatic Murine Carcinomas. Cancer Research, 2005, 65, 7485-7492.	0.9	27
21	The RhoGAP ARHGAP19 controls cytokinesis and chromosome segregation in T lymphocytes. Journal of Cell Science, 2014, 127, 400-10.	2.0	23
22	Isocitrate dehydrogenase (IDH)2 R140Q mutation induces myeloid and lymphoid neoplasms in mice. Leukemia, 2014, 28, 1343-1346.	7.2	18
23	AG-221, an Oral, Selective, First-in-Class, Potent IDH2-R140Q Mutant Inhibitor, Induces Differentiation in a Xenotransplant Model. Blood, 2014, 124, 3735-3735.	1.4	18
24	A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a Dâ€2â€hydroxyglutaric aciduria type II mouse model. Journal of Inherited Metabolic Disease, 2016, 39, 807-820.	3.6	11
25	TNFâ€Î± Potentiates ILâ€4/ILâ€13â€Induced ILâ€13Rα2 Expression. Annals of the New York Academy of Sciences 973, 207-209.	, <u>20</u> 02, 3.8	9
26	Phosphorylation of ARHGAP19 by CDK1 and ROCK regulates its subcellular localization and function during mitosis. Journal of Cell Science, 2018, 131, .	2.0	9
27	Familial hematological malignancies: new IDH2 mutation. Annals of Hematology, 2016, 95, 1943-1947.	1.8	7